303
Views
77
CrossRef citations to date
0
Altmetric
Original Research

Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study

, , , , , & show all
Pages 1549-1560 | Published online: 29 Oct 2015

Figures & data

Figure 1 Extent to which pain has interfered with daily life over the past 4 weeks.

Notes: Statistical analyses were primarily descriptive and correlative in nature. (A) Global HERO population, (B) US HERO population, and (C) By country.
Abbreviations: HERO, Hemophilia Experiences, Results and Opportunities; w/o, without.
Figure 1 Extent to which pain has interfered with daily life over the past 4 weeks.

Table 1 EQ-5D index by hemophilia type and treatment regimen for adult global and US HERO populations

Table 2 EQ-5D index by country

Table 3 EQ-5D index by age group

Figure 2 “VAS health” score for patients with and without inhibitors.

Notes: VAS was coded electronically as an 11-point categorical response based upon the nearest value (0–100). Statistical analyses were primarily descriptive and correlative in nature. (A) Global HERO population and (B) US HERO population.
Abbreviations: HERO, Hemophilia Experiences, Results and Opportunities; PWH, persons with hemophilia; VAS, visual analog scale.
Figure 2 “VAS health” score for patients with and without inhibitors.

Figure 3 Employment and bleed frequency by EQ-5D, pain interference, and self-reported arthritis.

Notes: Global HERO data shown in bar chart, US HERO data shown as diamonds above each scale. Statistical analyses were primarily descriptive and correlative in nature. aOne patient reporting EQ-5D mobility as “confined to bed” is not shown. bNo patient reported EQ-5D usual activities as “unable”. (A) Employment and (B) Bleed frequency.
Abbreviations: HERO, Hemophilia Experiences, Results and Opportunities; PWH, patients with hemophilia.
Figure 3 Employment and bleed frequency by EQ-5D, pain interference, and self-reported arthritis.

Figure 4 HCP utilization by EQ-5D, pain interference, and self-reported arthritis.

Notes: Global HERO data shown in bar chart, US HERO data shown as diamonds above each scale. Statistical analyses were primarily descriptive and correlative in nature. aTwo patients reporting EQ-5D mobility as “confined to bed” are not shown. bOne patient reporting EQ-5D usual activities as “unable to perform my usual activities” is not shown.
Abbreviations: HCP, health care practitioner; HERO, Hemophilia Experiences, Results and Opportunities; PWH, patients with hemophilia.
Figure 4 HCP utilization by EQ-5D, pain interference, and self-reported arthritis.

Table S1 Demographics of the eight-country post hoc analysis patient population